Current Report Filing (8-k)
June 21 2023 - 2:08PM
Edgar (US Regulatory)
0001355790
false
0001355790
2023-06-14
2023-06-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
June 14, 2023
INTERNATIONAL STEM CELL CORPORATION
(Exact name of registrant as specified in its
charter)
Delaware |
000-51891 |
20-4494098 |
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification Number) |
9745 Businesspark Ave, San Diego, California
92131
(Address of principal executive offices, including
zip code)
(760) 940-6383
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
None |
N/A |
N/A |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.07 Submission of Matters to a Vote of Security Holders
International Stem Cell Corporation (the “Company”)
held its Annual Meeting of Stockholders on June 14, 2023. The stockholders considered two proposals, which are described in more detail
in the Company’s definitive proxy statement dated April 28, 2023.
Proposal 1: Election of four directors to hold office until the 2024 Annual Meeting:
|
A. |
Directors elected by holders of Series D Preferred Stock: |
| |
FOR | | |
WITHHELD | |
Andrey Semechkin | |
| 2,457,143 | | |
| 0 | |
Russell Kern | |
| 2,457,143 | | |
| 0 | |
|
B. |
Directors elected by holders of all shares of stock (including shares of preferred stock voting on an as-converted basis): |
| |
FOR | | |
WITHHELD | |
Donald A. Wright | |
| 7,833,624 | | |
| 44,091 | |
Paul V. Maier | |
| 7,834,844 | | |
| 42,871 | |
Broker Non-Votes: none
All of the foregoing candidates were elected.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
INTERNATIONAL STEM CELL CORPORATION |
|
|
|
Date: June 21, 2023 |
By: |
|
/s/ Russell Kern |
|
|
|
Russell Kern |
|
|
|
Executive Vice President,
Chief Scientific Officer and
Principal Financial Officer |
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Jul 2024 to Aug 2024
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Aug 2023 to Aug 2024